A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Ustekinumab (Primary) ; Golimumab
  • Indications Spondylarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen; Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 11 Aug 2017 Planned End Date changed from 22 May 2019 to 16 Aug 2017.
    • 11 Aug 2017 Planned primary completion date changed from 19 Aug 2018 to 16 Aug 2017.
    • 27 Jul 2017 This trial has been completed in Portugal (end date: 2017-05-17).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top